Caverject

Erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. Adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

Intracavernosal inj Individualized dosage. Initial titration: Titrate dose based on erectile response until dose produce an erection suitable for intercourse not exceeding >60 min. If there is no response, a higher dose may be given after 1 hr but no >2 doses should be given w/in a 24-hr period. If a response occurs, there should be at least 1-day interval before next dose. Maintenance therapy: Recommend inj frequency: No more than once daily & 3 times wkly. Neurogenic etiology (spinal cord injury) Starting dose: 1.25 mcg. 2nd dose: 2.5 mcg. 3rd dose: 5 mcg. Additional increments of 5 mcg until optimal dose is achieved. Vasculogenic, psychogenic or mixed etiology Starting dose: 2.5 mcg. 2nd dose: 5 mcg (partial response), 7.5 mcg (no response). Additional increments of 5-10 mcg until optimal dose is achieved. Adjunct to diagnosis of erectile dysfunction A single dose that induces firm erection is used.

Hypersensitivity. Patients who have conditions that might predispose to priapism (eg, sickle cell anemia or trait, multiple myeloma or leukemia); w/ anatomical deformation of the penis (eg, angulation, cavernosal fibrosis, or Peyronie's disease); penile implants. Men for whom sexual activity is inadvisable or contraindicated. Women. Childn & newborns.

Drugs for Erectile Dysfunction & Ejaculatory Disorders

G04BE01 - alprostadil ; Belongs to the class of drugs used in erectile dysfunction.

POM